DEF 14A: Establishment Labs Holdings Inc. Announces Details for 2024 Annual Meeting of Shareholders

Establishment Labs Holdings Inc. will hold its 2024 annual meeting of shareholders on May 24, 2024, via live audio webcast.

Summary

• Establishment Labs Holdings Inc. will hold its 2024 annual meeting of shareholders on May 24, 2024, at 1:00 pm Eastern Time via live audio webcast.
• Shareholders of record as of April 4, 2024, are entitled to notice of and to vote at the Annual Meeting.
• The meeting will address the election of two director nominees, an advisory vote on executive compensation, and the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board recommends voting for the election of the director nominees, for the compensation of named executive officers, and for the ratification of the appointment of Marcum LLP.
• The company's revenue for 2023 was $165.2 million, a 2.2% increase from $161.7 million in 2022.
• Net losses for 2023 were $78.5 million, compared to $75.2 million in 2022.
• The company's cash balance as of December 31, 2023, was $40.0 million.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. Revenue increased slightly, and there were several strategic achievements. However, net losses also increased, and there is a potential capital raise. The sentiment is neutral to slightly positive.

Positives

• Revenue increased by 2.2% from 2022 to 2023, reaching $165.2 million.
• The company launched Motiva Implants in China and completed the first procedure with the Motiva Flora SmoothSilk Tissue Expander in the United States in January 2024.
• Regulatory approvals were obtained for Motiva Implants in China, the Motiva Flora SmoothSilk Tissue Expander in the United States, and various Motiva devices in Europe in November 2023.
• The company completed a two-year clinical study for Mia Femtech, showing potential for breast shape increase without general anesthesia.
• Zen, the latest passive RFID technology, was launched in certain areas in October 2023.
• The final module of the clinical trial for Motiva Implants in the United States was submitted to the FDA in February 2023.

Negatives

• Net losses increased from $75.2 million in 2022 to $78.5 million in 2023.

Risks

• The company's ability to achieve revenue targets and manage operating expenses effectively is crucial for future financial performance.
• The company's success depends on continued regulatory approvals and successful product launches.
• The company's future performance is subject to various risks, including those related to competition, market conditions, and regulatory changes.

Future Outlook

The company does not provide specific forward-looking statements in this document, but it outlines strategic initiatives and objectives for long-term value creation.

Management Comments

• Juan Jos Chacn Quirs, Board Member and Chief Executive Officer, cordially invites shareholders to attend the 2024 annual meeting.

Industry Context

The document provides insight into the company's governance and compensation practices, aligning with industry standards for publicly traded companies. The focus on innovation, regulatory approvals, and global expansion reflects key trends in the medical device industry.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like Artivion, Inspire Medical Systems, and Sientra, reflecting a mix of aesthetic and implantable device companies.
• The company aims to position its total revenues, market capitalization, and operating income at approximately the median relative to its peer group companies.
• The Compensation Committee's philosophy is that each executive's targeted total direct compensation should be at or below the 50th percentile of the targeted total direct compensation provided by its peer companies to similarly situated executives.

Corporate Governance

Related Party Transactions

• The company recorded revenue of $1.2 million for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of the Chief Executive Officer.
• The company paid Dr. Chacn Quirs, the brother of the Companys Chief Executive Officer Juan Jos Chacn Quirs, approximately $0.4 million for training services rendered.

Stakeholder Impact

• Shareholders have the opportunity to vote on key proposals, influencing the company's direction and governance.
• Executive compensation is designed to motivate executives to create long-term shareholder value.
• The company's performance and strategic initiatives impact employees, customers, and other stakeholders.

Next Steps

• Shareholders are urged to vote on the proposals outlined in the proxy statement.
• The Board will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The Audit Committee may appoint a different independent registered public accounting firm at any time if it determines that such a change would be in the best interests of the Company and its shareholders.

Key Dates

Keywords

annual meeting, proxy statement, directors, executive compensation, Marcum LLP, Establishment Labs, shareholders, voting, governance, financials